More Confident Cancer Care Decisions Start with Caris

MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric patients (ages 1+). It is also FDA approved for molecular profiling of solid tumors when used by a qualified healthcare professional following recognized professional guidelines (e.g., NCCN). The assay identifies patients who may benefit from treatment with certain targeted therapies.

Optional add-ons for IHC testing are available, please see intended use to learn more.​

Caris Assure® is an NGS-based test that measures circulating total nucleic acids using plasma and white blood cells from peripheral whole blood. This test is intended for patients with previously diagnosed solid tumors where tissue testing is infeasible and who may benefit from treatment with certain targeted therapies. Unlike many other liquid biopsy platforms, Caris Assure can detect both tumor-derived and incidental germline* variants. It can also filter out clonal hematopoiesis which is unrelated to the tumor and could lead to clinical false positives. These assay characteristics lead to superior liquid biopsy performance.​

Caris ChromoSeq™ is a whole-genome sequencing platform to detect and report genomic alterations considered clinically relevant in myeloid malignancies. Caris ChromoSeq helps identify clinically relevant genomic alterations including SNVs, indels, gene fusions, copy number alterations, and large-scale genomic changes to support treatment decision-making. This advanced molecular approach provides a more comprehensive view of genomic abnormalities than traditional cytogenetic methods alone, helping clinicians deliver more informed, personalized care for patients with blood cancers.